Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sihuan Pharmaceuticals Hong Kong IPO Draws Major Cornerstone Investors

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - An initial public offering in Hong Kong by Sihuan Pharmaceuticals Group has attracted major cornerstone investors, including billionaire investor George Soros, China Life Insurance (Overseas), and the Yun Feng Fund for a combined $190 million

You may also be interested in...



Sihuan Pharma Trades At 28 Percent Above IPO Target; Analysts Point To Risks

SHANGHAI - China's Sihuan Pharmaceutical Holdings Group far exceeded its target price in its debut on the Hong Kong stock market, ending the first day with shares trading at 28 percent above the price

Sihuan Pharma Trades At 28 Percent Above IPO Target; Analysts Point To Risks

SHANGHAI - China's Sihuan Pharmaceutical Holdings Group far exceeded its target price in its debut on the Hong Kong stock market, ending the first day with shares trading at 28 percent above the price

China's Largest Private Drug Distributor, Jointown, Seeks Initial Public Offering In Shanghai

SHANGHAI - To compete with the country's largest drug distributor SinoPharm, China's third-ranked Jointown recently filed for an initial public offering in Shanghai to raise roughly RMB 899.8 million ($135.4 million) to expand a distribution network in seven key regions across China

Related Content

UsernamePublicRestriction

Register

SC073346

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel